by Karl Denninger
Market-Ticker.org
“Here we’ve got an agent that more than doubles the levels of good cholesterol and lowers bad cholesterol and yet has no effect on clinical events,” lead study author Dr. Stephen Nicholls, a professor at Australia’s University of Adelaide and cardiologist at Royal Adelaide Hospital, said in a statement. “We were disappointed and surprised by the results.”
Got it?
More than doubling the level of allegedly-good cholesterol and lowering allegedly-bad cholesterol did not change your risk of having a “clinical event”, in other words, a heart attack or stroke.